Indications
Vials Menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.
Composition
- Active substance
- meningococcal group A, C, W-135 and Y conjugate vaccine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Menveo
- Active substance
- meningococcal group A, C, W-135 and Y conjugate vaccine
- ATC code
- J07AH08
- Therapeutic area
- Immunization, Meningitis, Meningococcal